Review of the Agnostic-Type Treatment Approach: Treating Cancer by Mutations, Not by Location

Review of the Agnostic-Type Treatment Approach: Treating Cancer by Mutations, Not by Location

Recent years has seen the discovery and outline of genetic alterations accountable for oncogenesis in all kinds of cancers, along with the discovering that some markers are actionable and may be focused by medicines. Such developments have enabled most cancers therapies to evolve from empirical palliative chemotherapy, with low possibilities of response or healing intent in most varieties of cancers, to focused remedy, with some research displaying promising ends in phrases of improved general response charges, general survival and high quality of life, though, like all new teams of medicines, with particular hostile impact profiles.

This therapy evolution is a significant improvement in most cancers remedy. Tumors have been initially categorised as stable or liquid tumors primarily based on their location in the human physique (stable organs or blood), which developed into the medical specialties of medical oncology and scientific hematology, respectively. Subsequently, tumors have been categorised by the organ they originate from, in the perception that the origin of the tumor would information its organic habits and would faciliate understanding of their mechanism of unfold and, probably, of the finest therapy method.

Although this latter method has achieved some success over the a few years it has been utilized, there have been main disappointments, notably in lung cancers for which palliative chemotherapy has solely been in a position to present a median survival of round 1 12 months and a whole remission charge of < 5%. We are actually understanding that this idea of most cancers pathophysiology is extra advanced, but in addition probably easy, and that one or a number of molecular aberrations are in all probability accountable for the origin of every most cancers. Various molecular alterations have been described, though the relevance of every alteration isn’t but totally understood. In this text, we spotlight scientific trial designs, biologic points, and regulatory points resulting in the improvement of medicines for tissue-agnostic therapy.

Impact of COVID-19 Pandemic on Dermatologists and Dermatology Practice

The COVID-19 pandemic has straight or not directly affected each human being on this planet. It’s influence on the healthcare system has been devastating. The medical fraternity throughout the world, together with India, is going through unprecedented challenges in striving to manage up with this catastrophic outbreak.
Like all different specialties, dermatology apply has been profoundly affected by this pandemic. Measures have been taken by dermatologists to manage the transmission of the virus, whereas offering well being care to sufferers in the constrained surroundings. Preventive measures akin to social distancing and hand hygienic practices together with affected person training is being prioritized. Dermatological conferences and occasions scheduled throughout the globe in the first half of 12 months 2020 have been both cancelled or postponed to discourage gatherings. Rationalization of sources and apply of teledermatology are being inspired in present situation. Non-urgent visits of the sufferers are being discouraged and elective dermatology procedures are being postponed.
Many nationwide and worldwide dermatology societies have lately proposed suggestions and advisories on utilization of biologicals and immunomodulators in current context of COVID-19 pandemic. Urticarial, erythematous, varicelliform, purpuric and livedoid rash in addition to aggravation of preexisting dermatological illnesses like rosacea, eczema, atopic dermatitis, and neurodermatitis rash have been reported in Covid-19 sufferers. Self medicines and poor compliance of dermatology sufferers along with lack of correct therapy protocols and monitoring are a severe concern in the current situation. Strategies for future course of motion, together with the dermatology particular pointers should be framed. This situation features a particular symposium on dermatology and COVID-19 having suggestions from particular curiosity teams (SIGs) of Indian Association of Dermatologists, Venereologists and Leprologists (IADVL) Academy on leprosy, dermatosurgery, lasers and dermoscopy.
 Review of the Agnostic-Type Treatment Approach: Treating Cancer by Mutations, Not by Location
Review of the Agnostic-Type Treatment Approach: Treating Cancer by Mutations, Not by Location

Personal Protective Equipment and Evidence-Based Advice for Surgical Departments throughout COVID-19

Background: Inconsistencies relating to the use of applicable private protecting tools (PPE) have raised issues for the security of surgical employees throughout the coronavirus illness 2019 (COVID-19) pandemic. This speedy assessment synthesises the literature that features enter from scientific consultants to offer evidence-based steerage for surgical companies.
Methods: The speedy assessment comprised of focused searches in PubMed and gray literature. Pertinent findings have been mentioned by a working group of scientific consultants, and consensus suggestions, in step with Australian and New Zealand Government pointers, have been formulated.
Results: There was a paucity of high-quality main research particularly investigating applicable surgical PPE for healthcare employees treating sufferers presumably contaminated with COVID-19. SARS-CoV-2 is succesful of aerosol, droplet and fomite transmission, making it important to reinforce normal an infection management measures with applicable PPE, particularly throughout surgical emergencies and aerosol-generating procedures. All organic materials needs to be handled a possible supply of SARS-COV-2. Staff should have formal coaching in the use of PPE and needs to be supervised by a colleague throughout donning and doffing. Patients with suspected or confirmed COVID-19 ought to put on a surgical masks throughout switch to and from theatre. Potential options exist in the literature to increase the use of surgical P2/N95 respirators in conditions of restricted provide.

Mouse Recombinant VEGF165 (VEGF-A) Protein (E.Coli), biologically active

VEGF35-R-100 100 ug
EUR 2242

Purified Recombinant Human BMP3 protein, Biologically active

BMP35-R-10 10 ug
EUR 408

Purified Recombinant Human BMP4 protein, Biologically active,

BMP45-R-10 10 ug
EUR 895

Purified Recombinant Human BMP4 protein, Biologically active

BMP45-R-5 5 ug
EUR 529

Purified Recombinant Human BMP6 protein, Biologically active

BMP65-R-20 20 ug
EUR 895

Human Recombinant VEGF121 Protein (Sf9), biologically active

VEGF24-R-10 10 ug
EUR 445

Human Recombinant VEGF121 Protein (Sf9), biologically active

VEGF24-R-100 100 ug
EUR 2425

Human Recombinant VEGF121 Protein (E.Coli), biologically active

VEGF25-R-10 10 ug
EUR 445

Human Recombinant VEGF121 Protein (E.Coli), biologically active

VEGF25-R-100 100 ug
EUR 2425

Human Recombinant VEGF165 Protein (E.Coli), biologically active

VEGF26-R-10 10 ug
EUR 445

Human Recombinant VEGF165 Protein (E.Coli), biologically active

VEGF26-R-100 100 ug
EUR 2242

Human Recombinant VEGF165 Protein (E.Coli), biologically active

VEGF26-R-1000 1000 ug
EUR 9185

Human Recombinant VEGF165 Protein (Sf9), biologically active

VEGF27-R-10 10 ug
EUR 445

Human Recombinant VEGF165 Protein (HEK), biologically active

VEGF27-R-100 100 ug
EUR 2425

Human Recombinant VEGF165 Protein (Sf9), biologically active

VEGF27-R-1000 1000 ug
EUR 9185

Human Calcineurin A-subunit protein WB +Ve control

CALNA12-C 100 ul
EUR 286

Human Calcineurin A-subunit Control/blocking peptide

CALNA12-P 100 ug
EUR 164

Monoclonal Anti-Human Calcineurin A-subunit ascites

CALNA13-M 100 ul
EUR 482

Calcineurin A

MO15055 100 ug
EUR 383

Purified (E.Coli) Recombinant Human BMP6 protein, Biologically active

BMP65-R-10 10 ug
EUR 529

Human Recombinant (E.Coli) Purified Noggin protein, biologically active

NOGN15-R-20 20 ug
EUR 469

Human Pancreatic Lipase (partially pure) biologically active

PLIP15-N 10 U
EUR 286

Recombinant purified Human Endostatin protein (P. Pastoris) biologically active

ENST13-R-100 100 ug
EUR 469

Recombinant purified Human Endostatin protein (P. Pastoris) biologically active

ENST13-R-1000 1000 ug
EUR 1626

Recombinant purified Human Endostatin protein (P. Pastoris) biologically active

ENST13-R-250 250 ug
EUR 712

Purified (CHO cells) Recombinant Human BMP7 protein, Biologically active

BMP75-R-10 10 ug
EUR 895

Recombinant (E. coli) purified Human Angiogenin protein, biologically active

ANGN15-R-50 50 ug
EUR 773

Rabbit Anti-bovine Calcineurin (A+B subunits) protein, IgG, aff pure

CALN11-A 100 ug
EUR 482

Mouse Recombinant Purified Noggin-Fc protein, biologically active

NOGN25-R-10 10 ug
EUR 347

Mouse Recombinant Purified Noggin-Fc protein, biologically active

NOGN25-R-25 25 ug
EUR 651

anti-Calcineurin A

YF-PA24445 50 ul
EUR 334
Description: Mouse polyclonal to Calcineurin A

Calcineurin A Antibody

3075-100
EUR 338

Calcineurin A Antibody

3075-30T
EUR 146

Calcineurin A antibody

20R-1444 100 ug
EUR 673
Description: Rabbit polyclonal Calcineurin A antibody

Calcineurin A antibody

70R-11595 100 ug
EUR 436
Description: Rabbit polyclonal Calcineurin A antibody

Calcineurin A Antibody

49514-100ul 100ul
EUR 333

Calcineurin A Antibody

49514-50ul 50ul
EUR 239

Purified (E.Coli) Recombinant Human BMP2 protein, Biologically active, Carrier free

BMP25-R-10 10 ug
EUR 895

Purified Human Angiostatin (Kringles 1-4) protein (>98%), biologically active

ANST11-R 100 ug
EUR 347

Recombinant purified human GST-alpha (GST-A1) protein biologically active

GSTA15-R-100 100 ug
EUR 834

Recombinant purified human GST-alpha (GST-A1) protein biologically active

GSTA15-R-25 25 ug
EUR 347

Recombinant purified human GST-mu (GST-M1) protein biologically active

GSTM25-R-100 100 ug
EUR 834

Recombinant purified human GST-mu (GST-M1) protein biologically active

GSTM25-R-25 25 ug
EUR 347

Recombinant purified human GST-pi (GST-P1) protein biologically active

GSTP35-R-100 100 ug
EUR 834

Recombinant purified human GST-pi (GST-P1) protein biologically active

GSTP35-R-25 25 ug
EUR 347

Human Recombinant EG-VEGF Protein (84aa, E. Coli), biologically active

VEGF36-R-100 100 ug
EUR 1991

Human Recombinant EG-VEGF Protein (84aa, E. coli), biologically active

VEGF36-R-20 20 ug
EUR 773

Human Recombinant EG-VEGF Protein (84aa, E. coli), biologically active

VEGF36-R-5 5 ug
EUR 324

Mouse Recombinant Purified Noggin protein (E. coli), biologically active

NOGN26-R-20 20 ug
EUR 651

Mouse Recombinant Purified Noggin protein (E. coli), biologically active

NOGN26-R-5 5 ug
EUR 286

Rat Recombinant VEGF152 (VEGF-C) Protein (Sf9), biologically active

VEGF31-R-10 10 ug
EUR 445

Rat Recombinant VEGF129 (VEGF-C) Protein (Sf9), biologically active

VEGF32-R-10 10 ug
EUR 445

Rat Recombinant VEGF129 (VEGF-C) Protein (Sf9), biologically active

VEGF32-R-100 100 ug
EUR 2425

Antibody for Human Calcineurin A

SPC-175D-A390 0.1mg
EUR 379
Description: A polyclonal antibody for Calcineurin A from Human | Mouse | Rat | Dog | rabbit. The antibody is produced in rabbit after immunization with human Calcineurin A peptide (AA 264-283). The Antibody is tested and validated for WB, IHC, ICC/IF, IP assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:120), IHC (1:100). This Calcineurin A antibody is conjugated to ATTO 390.

Antibody for Human Calcineurin A

SPC-175D-A488 0.1mg
EUR 378
Description: A polyclonal antibody for Calcineurin A from Human | Mouse | Rat | Dog | rabbit. The antibody is produced in rabbit after immunization with human Calcineurin A peptide (AA 264-283). The Antibody is tested and validated for WB, IHC, ICC/IF, IP assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:120), IHC (1:100). This Calcineurin A antibody is conjugated to ATTO 488.

Antibody for Human Calcineurin A

SPC-175D-A594 0.1mg
EUR 378
Description: A polyclonal antibody for Calcineurin A from Human | Mouse | Rat | Dog | rabbit. The antibody is produced in rabbit after immunization with human Calcineurin A peptide (AA 264-283). The Antibody is tested and validated for WB, IHC, ICC/IF, IP assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:120), IHC (1:100). This Calcineurin A antibody is conjugated to ATTO 594.

Antibody for Human Calcineurin A

SPC-175D-A633 0.1mg
EUR 378
Description: A polyclonal antibody for Calcineurin A from Human | Mouse | Rat | Dog | rabbit. The antibody is produced in rabbit after immunization with human Calcineurin A peptide (AA 264-283). The Antibody is tested and validated for WB, IHC, ICC/IF, IP assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:120), IHC (1:100). This Calcineurin A antibody is conjugated to ATTO 633.

Antibody for Human Calcineurin A

SPC-175D-A655 0.1mg
EUR 378
Description: A polyclonal antibody for Calcineurin A from Human | Mouse | Rat | Dog | rabbit. The antibody is produced in rabbit after immunization with human Calcineurin A peptide (AA 264-283). The Antibody is tested and validated for WB, IHC, ICC/IF, IP assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:120), IHC (1:100). This Calcineurin A antibody is conjugated to ATTO 655.

Antibody for Human Calcineurin A

SPC-175D-A680 0.1mg
EUR 378
Description: A polyclonal antibody for Calcineurin A from Human | Mouse | Rat | Dog | rabbit. The antibody is produced in rabbit after immunization with human Calcineurin A peptide (AA 264-283). The Antibody is tested and validated for WB, IHC, ICC/IF, IP assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:120), IHC (1:100). This Calcineurin A antibody is conjugated to ATTO 680.

Antibody for Human Calcineurin A

SPC-175D-A700 0.1mg
EUR 378
Description: A polyclonal antibody for Calcineurin A from Human | Mouse | Rat | Dog | rabbit. The antibody is produced in rabbit after immunization with human Calcineurin A peptide (AA 264-283). The Antibody is tested and validated for WB, IHC, ICC/IF, IP assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:120), IHC (1:100). This Calcineurin A antibody is conjugated to ATTO 700.

Antibody for Human Calcineurin A

SPC-175D-ALP 0.1mg
EUR 372
Description: A polyclonal antibody for Calcineurin A from Human | Mouse | Rat | Dog | rabbit. The antibody is produced in rabbit after immunization with human Calcineurin A peptide (AA 264-283). The Antibody is tested and validated for WB, IHC, ICC/IF, IP assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:120), IHC (1:100). This Calcineurin A antibody is conjugated to Alkaline Phosphatase.

Antibody for Human Calcineurin A

SPC-175D-APC 0.1mg
EUR 377
Description: A polyclonal antibody for Calcineurin A from Human | Mouse | Rat | Dog | rabbit. The antibody is produced in rabbit after immunization with human Calcineurin A peptide (AA 264-283). The Antibody is tested and validated for WB, IHC, ICC/IF, IP assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:120), IHC (1:100). This Calcineurin A antibody is conjugated to APC .

Antibody for Human Calcineurin A

SPC-175D-APCCY7 0.1mg
EUR 450
Description: A polyclonal antibody for Calcineurin A from Human | Mouse | Rat | Dog | rabbit. The antibody is produced in rabbit after immunization with human Calcineurin A peptide (AA 264-283). The Antibody is tested and validated for WB, IHC, ICC/IF, IP assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:120), IHC (1:100). This Calcineurin A antibody is conjugated to APC/Cy7.

Antibody for Human Calcineurin A

SPC-175D-BI 0.1mg
EUR 374
Description: A polyclonal antibody for Calcineurin A from Human | Mouse | Rat | Dog | rabbit. The antibody is produced in rabbit after immunization with human Calcineurin A peptide (AA 264-283). The Antibody is tested and validated for WB, IHC, ICC/IF, IP assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:120), IHC (1:100). This Calcineurin A antibody is conjugated to Biotin.

Antibody for Human Calcineurin A

SPC-175D-DY350 0.1mg
EUR 393
Description: A polyclonal antibody for Calcineurin A from Human | Mouse | Rat | Dog | rabbit. The antibody is produced in rabbit after immunization with human Calcineurin A peptide (AA 264-283). The Antibody is tested and validated for WB, IHC, ICC/IF, IP assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:120), IHC (1:100). This Calcineurin A antibody is conjugated to Dylight 350.

Antibody for Human Calcineurin A

SPC-175D-DY405 0.1mg
EUR 381
Description: A polyclonal antibody for Calcineurin A from Human | Mouse | Rat | Dog | rabbit. The antibody is produced in rabbit after immunization with human Calcineurin A peptide (AA 264-283). The Antibody is tested and validated for WB, IHC, ICC/IF, IP assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:120), IHC (1:100). This Calcineurin A antibody is conjugated to Dylight 405.

Antibody for Human Calcineurin A

SPC-175D-DY488 0.1mg
EUR 371
Description: A polyclonal antibody for Calcineurin A from Human | Mouse | Rat | Dog | rabbit. The antibody is produced in rabbit after immunization with human Calcineurin A peptide (AA 264-283). The Antibody is tested and validated for WB, IHC, ICC/IF, IP assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:120), IHC (1:100). This Calcineurin A antibody is conjugated to Dylight 488.

Antibody for Human Calcineurin A

SPC-175D-DY594 0.1mg
EUR 373
Description: A polyclonal antibody for Calcineurin A from Human | Mouse | Rat | Dog | rabbit. The antibody is produced in rabbit after immunization with human Calcineurin A peptide (AA 264-283). The Antibody is tested and validated for WB, IHC, ICC/IF, IP assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:120), IHC (1:100). This Calcineurin A antibody is conjugated to Dylight 594.

Antibody for Human Calcineurin A

SPC-175D-DY633 0.1mg
EUR 368
Description: A polyclonal antibody for Calcineurin A from Human | Mouse | Rat | Dog | rabbit. The antibody is produced in rabbit after immunization with human Calcineurin A peptide (AA 264-283). The Antibody is tested and validated for WB, IHC, ICC/IF, IP assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:120), IHC (1:100). This Calcineurin A antibody is conjugated to Dylight 633.

Antibody for Human Calcineurin A

SPC-175D-FITC 0.1mg
EUR 370
Description: A polyclonal antibody for Calcineurin A from Human | Mouse | Rat | Dog | rabbit. The antibody is produced in rabbit after immunization with human Calcineurin A peptide (AA 264-283). The Antibody is tested and validated for WB, IHC, ICC/IF, IP assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:120), IHC (1:100). This Calcineurin A antibody is conjugated to FITC.

Antibody for Human Calcineurin A

SPC-175D-HRP 0.1mg
EUR 366
Description: A polyclonal antibody for Calcineurin A from Human | Mouse | Rat | Dog | rabbit. The antibody is produced in rabbit after immunization with human Calcineurin A peptide (AA 264-283). The Antibody is tested and validated for WB, IHC, ICC/IF, IP assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:120), IHC (1:100). This Calcineurin A antibody is conjugated to HRP.

Antibody for Human Calcineurin A

SPC-175D-P594 0.1mg
EUR 385
Description: A polyclonal antibody for Calcineurin A from Human | Mouse | Rat | Dog | rabbit. The antibody is produced in rabbit after immunization with human Calcineurin A peptide (AA 264-283). The Antibody is tested and validated for WB, IHC, ICC/IF, IP assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:120), IHC (1:100). This Calcineurin A antibody is conjugated to PE/ATTO 594.

Antibody for Human Calcineurin A

SPC-175D-PCP 0.1mg
EUR 377
Description: A polyclonal antibody for Calcineurin A from Human | Mouse | Rat | Dog | rabbit. The antibody is produced in rabbit after immunization with human Calcineurin A peptide (AA 264-283). The Antibody is tested and validated for WB, IHC, ICC/IF, IP assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:120), IHC (1:100). This Calcineurin A antibody is conjugated to PerCP.

Antibody for Human Calcineurin A

SPC-175D-RPE 0.1mg
EUR 375
Description: A polyclonal antibody for Calcineurin A from Human | Mouse | Rat | Dog | rabbit. The antibody is produced in rabbit after immunization with human Calcineurin A peptide (AA 264-283). The Antibody is tested and validated for WB, IHC, ICC/IF, IP assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:120), IHC (1:100). This Calcineurin A antibody is conjugated to RPE .

Antibody for Human Calcineurin A

SPC-175D-STR 0.1mg
EUR 376
Description: A polyclonal antibody for Calcineurin A from Human | Mouse | Rat | Dog | rabbit. The antibody is produced in rabbit after immunization with human Calcineurin A peptide (AA 264-283). The Antibody is tested and validated for WB, IHC, ICC/IF, IP assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:120), IHC (1:100). This Calcineurin A antibody is conjugated to Streptavidin.

Antibody for Human Calcineurin A

SPC-175S 0.012mg
EUR 65
Description: A polyclonal antibody for Calcineurin A from Human | Mouse | Rat | Dog | rabbit. The antibody is produced in rabbit after immunization with human Calcineurin A peptide (AA 264-283). The Antibody is tested and validated for WB, IHC, ICC/IF, IP assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:120), IHC (1:100). This Calcineurin A antibody is unconjugated.

Antibody for Human Calcineurin A

SPC-175D 0.1mg
EUR 332
Description: A polyclonal antibody for Calcineurin A from Human | Mouse | Rat | Dog | rabbit. The antibody is produced in rabbit after immunization with human Calcineurin A peptide (AA 264-283). The Antibody is tested and validated for WB, IHC, ICC/IF, IP assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:120), IHC (1:100). This Calcineurin A antibody is unconjugated.

Antibody for Human Calcineurin A

SPC-175D-A565 0.1mg
EUR 378
Description: A polyclonal antibody for Calcineurin A from Human | Mouse | Rat | Dog | rabbit. The antibody is produced in rabbit after immunization with human Calcineurin A peptide (AA 264-283). The Antibody is tested and validated for WB, IHC, ICC/IF, IP assays with the following recommended dilutions: WB (1:1000), ICC/IF (1:120), IHC (1:100). This Calcineurin A antibody is conjugated to ATTO 565.

Lipase, Human Pancreas (biologically active) antigen grade (.95% pure)

PLIP15-N-10 10 ug
EUR 286

Activin-A Active Protein

20-abx260392
  • EUR 1970.00
  • EUR 230.00
  • EUR 328.00
  • 100 ug
  • 1 µg
  • 5 ug

Activin-A, Active Protein

20-abx262945
  • EUR 328.00
  • EUR 6397.00
  • EUR 230.00
  • 10 ug
  • 1 mg
  • 2 µg

Anti-Calcineurin A (2G8)

YF-MA10714 100 ug
EUR 363
Description: Mouse monoclonal to Calcineurin A

Calcineurin A Blocking Peptide

3075BP-50
EUR 153

Calcineurin A Blocking Peptide

33R-10618 50 ug
EUR 191
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Calcineurin A antibody, catalog no. 70R-11595

Anti-Calcineurin A Antibody

A07303 200ug/vial
EUR 442
Description: Rabbit Polyclonal Calcineurin A Antibody. Validated in IP, WB and tested in Human, Mouse, Rat.

Calcineurin A Rabbit mAb

A4346-100ul 100 ul
EUR 410

Calcineurin A Rabbit mAb

A4346-200ul 200 ul
EUR 571

Calcineurin A Rabbit mAb

A4346-20ul 20 ul
EUR 221

Calcineurin A Rabbit mAb

A4346-50ul 50 ul
EUR 287

Calcineurin A (CALNA) Antibody

abx448453-100ug 100 ug
EUR 495

Calcineurin A Antibody (Biotin)

abx446035-100ug 100 ug
EUR 551

Calcineurin A Antibody (FITC)

abx446036-100ug 100 ug
EUR 551

Calcineurin A Antibody (HRP)

abx446037-100ug 100 ug
EUR 537

Polyclonal Calcineurin A Antibody

APR15221G 0.1mg
EUR 484
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human Calcineurin A . This antibody is tested and proven to work in the following applications:

Calcineurin A Conjugated Antibody

C49514 100ul
EUR 397

Human Recombinant (E.Coli) Angiostatin Kringles 1-3 purified protein biologically active

ANKR131-R-250 250 ug
EUR 773

Human Recombinant (E.Coli) Angiostatin Kringles 1-3 purified protein biologically active

ANKR131-R-50 50 ug
EUR 225

Recombinant purified Human Heme Oxygenase 2 (HO-2) protein (biologically active)

HO25-R-25 25 ug
EUR 347

Calmodulin-Dependent Calcineurin A Subunit Gamma Isoform (CALNA3) Antibody

20-abx114853
  • EUR 732.00
  • EUR 398.00
  • 150 ul
  • 50 ul

Calmodulin-Dependent Calcineurin A Subunit Gamma Isoform (CALNA3) Antibody

20-abx142165
  • EUR 370.00
  • EUR 606.00
  • EUR 314.00
  • 100 ul
  • 200 ul
  • 50 ul

Human Calcineurin B -subunit protein WB +Ve control

CALNB21-C 100 ul
EUR 286

Activin-A Human Recombinant Protein, Active

PROTP08476-2 Regular: 10ug
EUR 317
Description: Active form Activin-A Human Recombinant produced in e.coli is a homodimeric, non-glycosylated, polypeptide chain containing 2 x 117 amino acids and having a molecular weight of 26.2kDa.;The Active form Activin-A is purified by standard chromatographic techniques.

Human Granzyme A (GZMA) Protein (Active)

20-abx655652
  • EUR 1191.00
  • EUR 425.00
  • EUR 4017.00
  • EUR 1455.00
  • EUR 815.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Recombinant Transforming Growth Factor-alpha (TGF-alpha), biologically active

TGFA15-R-100 100 ug
EUR 529

Human Recombinant Transforming Growth Factor-alpha (TGF-alpha), biologically active

TGFA15-R-1000 1000 ug
EUR 3521

Human Recombinant Transforming Growth Factor-alpha (TGF-alpha), biologically active

TGFA15-R-20 20 ug
EUR 225

Active Platelet Derived Growth Factor Subunit A (PDGFA)

4-APA528Hu01
  • EUR 772.00
  • EUR 310.00
  • EUR 2620.00
  • EUR 940.00
  • EUR 1780.00
  • EUR 580.00
  • EUR 6400.00
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
Description: Recombinant Human Platelet Derived Growth Factor Subunit A expressed in: E.coli

Active Platelet Derived Growth Factor Subunit A (PDGFA)

4-APA528Mu01
  • EUR 798.88
  • EUR 317.00
  • EUR 2720.80
  • EUR 973.60
  • EUR 1847.20
  • EUR 598.00
  • EUR 6652.00
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
Description: Recombinant Mouse Platelet Derived Growth Factor Subunit A expressed in: Available from E.coli, Yeast, Baculovirus and Mammalian cells

Recombinant purified human GST-alpha 3 (GST A3-3) protein biologically active

GSTA35-R-100 100 ug
EUR 834

Recombinant purified human GST-alpha 3 (GST A3-3) protein biologically active

GSTA35-R-25 25 ug
EUR 347

Recombinant purified human GST-T1-1 (GST T1-1) protein biologically active

GSTT45-R-100 100 ug
EUR 834

Recombinant purified human GST-T1-1 (GST T1-1) protein biologically active

GSTT45-R-25 25 ug
EUR 347

Mouse Platelet Derived Growth Factor Subunit A (PDGFA) Protein (Active)

20-abx651432
  • EUR 1094.00
  • EUR 398.00
  • EUR 3641.00
  • EUR 1330.00
  • EUR 746.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Activin-A HEK-Active Protein

20-abx263137
  • EUR 1372.00
  • EUR 328.00
  • EUR 230.00
  • 100 ug
  • 10 ug
  • 2 µg

Calcineurin A recombinant monoclonal antibody

A5781 100ul X 3
EUR 595
Description: A recombinant monoclonal antibody from rabbit against human Calcineurin A for WB, IF,ELISA

Anti-Calcineurin A/PPP3CA Antibody

PB9382 100ug/vial
EUR 294

Calcineurin A (CALNA) Antibody (ALP)

abx446033-100ug 100 ug
EUR 551

Calcineurin A (CALNA) Antibody (APC)

abx446034-100ug 100 ug
EUR 551

Calcineurin A (CALNA) Antibody (PerCP)

abx446039-100ug 100 ug
EUR 551

Calcineurin A (CALNA) Antibody (RPE)

abx446040-100ug 100 ug
EUR 551

Calcineurin A (CALNA) Antibody (Streptavidin)

abx446041-100ug 100 ug
EUR 551

Recombinant purified Mouse Endostatin protein (P. Pastoris) biologically active, low endotoxin

ENST15-R-100 100 ug
EUR 469

Recombinant purified Mouse Endostatin protein (P. Pastoris) biologically active, low endotoxin

ENST15-R-250 250 ug
EUR 712

Recombinant purified Rat Heme Oxygenase 1 (HO-1) protein (biologically active)

HO15-R-25 25 ug
EUR 347

Human Calcineurin subunit B type 2 (PPP3R2)

1-CSB-EP856978HU
  • EUR 380.00
  • EUR 214.00
  • EUR 1309.00
  • EUR 560.00
  • EUR 873.00
  • EUR 262.00
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Human Calcineurin subunit B type 2(PPP3R2) expressed in E.coli

Recombinant Human Activin-A Active

7-00004 1ug Ask for price
Conclusion: PPE is suggested for all high-risk procedures and when a affected person’s COVID-19 standing is unknown. Surgical departments ought to facilitate staggered rostering, distant assembly attendance, and self-isolation of symptomatic employees. Vulnerable surgical employees needs to be recognized and excluded from operations with a excessive danger of COVID-19 an infection.

Leave a Comment

Your email address will not be published.

Scroll to Top